AWARDDEFINITIVE CONTRACTSmall business
Definitive contract HHSN272201700011CCHRYSALIS BIOTHERAPEUTICS, INC.
Overview
Award facts
- Net obligations
- $6.95M
- $6,954,509of $6.95M potential value
- Outlays (paid to date)
- $1.50M
- $1.50M paid of $6.95M obligated$1,500,152
- Period of performance
- Jan 30, 2017 to Aug 31, 2021
- Ended
- Modifications
- 17
- Latest action Apr 5, 2023
- Contract type
- Definitive contract
- PIID HHSN272201700011C
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
IGF::OT::IGF TP508: A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
Dates and value
- Award date
- Signed on Jan 30, 2017
- Potential end of performance
- Aug 30, 2021
- Current value
- $6,954,509Base and exercised options
- Potential value (if all options are exercised)
- $6,954,509
Obligations by fiscal year of action
- FY2023: -$0 (de-obligation)
- FY2020: $1,500,152
- FY2019: $1,864,898
- FY2018: $1,984,084
- FY2017: $1,605,375
Total across 5 fiscal years: $6,954,509
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Apr 5, 2023. View on USAspending · Recipient on SAM.gov
Recipient
LocationGALVESTON, TX
UEIXW1VFGGRLDW3
CAGE code5DAY4
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyCHRYSALIS BIOTHERAPEUTICS, INC.
Business types and certifications
For-profit organizationCorporation (not tax-exempt)
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- National institute of allergy and infectious diseases (0885); Nih office of the director (0846)Program activities075-0846, 075-0885Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Galveston, Texas 77550-1532
- Congressional district (place of performance)
- TX-14As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost plus fixed feeU
- Offers received
- 29
Solicitation and notices
- Solicitation ID
- BAANIAIDNIHAI2015042(as reported)
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- Igf::ot::igf TP508: a novel nuclear countermeasure targeting endothelial cells and stem cellsto comb
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not a bundled requirementD
- Consolidated requirement
- No
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Jan 30, 2017Base obligation at award: $1,605,375
- Latest action
- Apr 5, 2023 — Funding onlyModification P00017; obligation change -$0; funding only: changes obligations, not scope
- Latest substantive action
- Jul 28, 2020 — Supplemental agreement (within scope)Modification P00012; obligation change +$587,995
- Latest funding action
- Apr 5, 2023 — Funding onlyModification P00017; obligation change -$0; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Other administrative action13
- Option exercised2
- Supplemental agreement (within scope)1
- Funding only1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$0
- Latest action: change in base and all options
- -$0
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 18
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2017/2017-0846-000
- 075-2018/2018-0846-000
- 075-2019/2019-0846-000
- 075-2020/2024-0885-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- L: Emergency P.L. 116-123
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- COVID-19 supplemental obligations
- $1,500,152
- COVID-19 supplemental outlays
- $1,500,152